Pharmala Biotech Holdings Inc C.MDMA

Alternate Symbol(s): MDXXF

PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines: the manufacture of MDMA and MDXX class molecules for sale to clinical researchers in both the commercial and academic sphere, the research and development of novel MDXX class compounds which offer unique benefits above and beyond known substances, and the development of novel delivery mechanisms for MDMA and MDXX class compounds. Its research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. It works with laboratories across Canada to develop novel processes for the supply of LaNeo MDMA and other MDXX substances.

CSE:MDMA - Post by User

Pharmala Biotech Holdings Inc > FDA Decision

<< Previous

Bullboard Posts

Next >>

Comment by inviolablspiriton Aug 12, 2024 10:47pm

41 Views

Post# 36175766

RE:Re: FDA Decision

Thanks! However, I don't feel the stock should have taken any hit today with the patent announcement. The FDA's panel vote had already done more damage than this company deserved considering they don't do business in the US. With the patent in hand now I hope Nick can get on with forming partnerships in Europe and Sout America.

<< Previous

Bullboard Posts

Next >>

AI companies to invest in